Cybin Inc. (NEO:CYBN / NYSE American:CYBN) a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking at the 26th Annual Milken Institute Global Conference on a panel entitled “Progress and Innovation: The Dawning of a New Day in Treating Mental Health.” The panel will take place on Tuesday, May 2, 2023, at 8:30 a.m. PT / 11:30 a.m. ET at The Beverly Hilton, Beverly Hills, CA. The Milken Institute is a nonprofit, nonpartisan think tank dedicated to connecting resources and innovation so the best ideas can succeed.
To access the live panel discussion, please click here. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page. For more information on the Milken Institute and the upcoming conference. visit www.milkeninstitute.org.
“Our work is focused on developing safe and effective psychedelic-based treatments for mental health conditions that are designed to achieve better clinical outcomes with fewer side effects for patients. The Milken Institute Global Conference provides an ideal opportunity to engage with global thought leaders working to improve the mental health landscape and to share the innovative clinical work that Cybin is doing to address the significant unmet need for new treatment options for people suffering from these devastating conditions.”
Doug Drysdale, Cybin’s Chief Executive Officer.
Current treatments for depression and other mental health disorders have limited effectiveness, leaving a treatment gap for many patients. According to the World Health Organization, there are more than 800,000 suicides each year globally. Up to 30% of people with depression do not respond to traditional antidepressant treatments. Emerging research has demonstrated the potential for psychedelic-based treatment to improve symptoms and quality of life for patients with mental health conditions such as Major Depressive Disorder and Generalized Anxiety Disorder, two indications that Cybin is targeting with its clinical development programs.
About Cybin
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.
Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.